Markets

Cytokinetics, Incorporated (CYTK) Soars: Stock Up 26% in Session - Tale of the Tape

Cytokinetics, Incorporated ( CYTK ) was a big mover last session, as its shares surged over 26% on the day. The surge came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the company since Jan 23, as the stock is now down almost 4%.

In the last 30-day frame, the company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's move higher lasts.

Cytokinetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other better-ranked stocks in the medical sector include Gentium S.p.A ( GENT ), Emergent BioSolutions, Inc. ( EBS ) and Actelion Ltd. ( ALIOF ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

ACTELION LTD (ALIOF): Get Free Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

EMERGENT BIOSOL (EBS): Free Stock Analysis Report

GENTIUM SPA-ADR (GENT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTK EBS

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More